
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt, please contact your stockbroker or the Company Secretary.

If you have sold or transferred your shares, please inform the Company Secretary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. immediately.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

€ - 9 w • 1 8 « p ... P " ® ! •

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

2023 WORK REPORT OF THE BOARD OF DIRECTORS
2023 WORK REPORT OF THE SUPERVISORY COMMITTEE
2023 ANNUAL REPORT AND ITS SUMMARY, H SHARES RESULTS ANNOUNCEMENT,
H SHARES 2023 ANNUAL REPORT, 2023 CORPORATE GOVERNANCE REPORT AND
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2023 FINAL FINANCIAL REPORT
2023 PROFIT DISTRIBUTION PROPOSAL
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT
USING INTERNAL FUNDS
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2024
THE SHAREHOLDERS' RETURN PLAN FOR THE NEXT THREE YEARS (2024-2026)
RE-APPOINTMENT OF AUDITORS OF THE COMPANY
AND
NOTICE OF THE 2023 ANNUAL GENERAL MEETING









AGM6

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms shall have the following meanings:

- 1. "Contract" means any agreement, written or oral, between the Government and the Contractor, including any amendments, modifications, or supplements thereto.
- 2. "Contractor" means the person or entity who has entered into a contract with the Government.
- 3. "Contract Price" means the total amount of money payable by the Government to the Contractor under the contract.
- 4. "Contract Documents" means the contract, including all specifications, drawings, and conditions of contract.
- 5. "Contractor's Proposal" means the offer submitted by the Contractor to the Government.
- 6. "Contractor's Performance" means the Contractor's fulfillment of the obligations under the contract.
- 7. "Contractor's Obligations" means the duties and responsibilities of the Contractor under the contract.
- 8. "Contractor's Rights" means the entitlements and benefits of the Contractor under the contract.
- 9. "Contractor's Breach" means the Contractor's failure to perform its obligations under the contract.
- 10. "Contractor's Default" means the Contractor's failure to perform its obligations under the contract, resulting in the termination of the contract.
- 11. "Contractor's Termination" means the termination of the contract by the Government.
- 12. "Contractor's Termination Fee" means the amount of money payable by the Contractor to the Government upon termination of the contract.
- 13. "Contractor's Termination Fee" means the amount of money payable by the Contractor to the Government upon termination of the contract.
- 14. "Contractor's Termination Fee" means the amount of money payable by the Contractor to the Government upon termination of the contract.
- 15. "Contractor's Termination Fee" means the amount of money payable by the Contractor to the Government upon termination of the contract.

DEFINITIONS

!		
-▲-▲-		3
-▲-▲-		3
-▲-▲-▲ 3		-Ç N t ø Ô /
		
-▲-▲-		3
-▲-▲-▲ 3		



LETTER FROM THE BOARD

1. INTRODUCTION

Dear Shareholders,

Good afternoon,

I am pleased to have the opportunity to meet with you today.

I will be discussing the following items:

1. The financial performance of the Company for the year ended 31 December 2023.

2. The proposed dividend for the year.

3. The proposed remuneration of the Directors for the year.

4. The proposed appointment of the independent non-executive Director.

5. The proposed appointment of the independent non-executive Director.

Thank you.

I will be available to answer your questions during the meeting.

I look forward to meeting you.

2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

i. 2023 Work Report of the Board of Directors

The Board of Directors has reviewed the financial performance of the Company for the year ended 31 December 2023. The Company has achieved a profit of HK\$1,234,567, which is an increase of 12% compared to the profit of HK\$1,102,345 for the year ended 31 December 2022.

The Board of Directors has also reviewed the financial performance of the Company for the year ended 31 December 2023. The Company has achieved a profit of HK\$1,234,567, which is an increase of 12% compared to the profit of HK\$1,102,345 for the year ended 31 December 2022.

LETTER FROM THE BOARD

vi. Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds

▲ 2024年1月1日至2024年12月31日止，本公司購買了多項財富管理產品，並使用內部資金進行現金流管理。此舉旨在優化資產配置，提高資金使用效率，並為股東創造長期價值。相關數據如下：

項目	金額 (萬元)
購買財富管理產品	1,200.00
現金流管理支出	800.00
合計	2,000.00

▲ 以上各項支出均符合公司財務政策及相關法規要求。未來，我們將繼續關注市場動向，靈活調整投資策略，以實現公司可持續發展目標。

vii. Application for Credit Line and Providing Guarantee to Certain Banks for 2024

▲ 2024年，本公司向多家銀行申請了總額為人民幣1.5億元的新增信用額度，並為部分銀行提供了擔保。此舉是為了滿足公司日常經營及未來發展所需的資金需求，確保資金鏈的穩定。相關情況如下：

銀行名稱	信用額度 (萬元)	擔保金額 (萬元)
中國工商銀行	5,000.00	3,000.00
中國銀行	4,000.00	2,000.00
交通銀行	3,000.00	1,500.00
其他銀行	3,000.00	1,500.00
合計	15,000.00	8,000.00

▲ 目前，所有信用額度均已獲批，且公司與各銀行保持良好的合作關係。未來，我們將根據實際需要，合理運用這些信用額度，確保公司資金安全。

viii. The Shareholders' Return Plan for the Next Three Years (2024-2026)

▲ 為回報股東對公司的長期支持，本公司制定了未來三年（2024-2026年）的股東回報計劃。該計劃將根據公司盈利情況及市場環境，通過現金分紅、股票回购等方式，為股東提供合理的回報。具體安排如下：

年份	現金分紅 (萬元)	股票回购 (萬元)
2024年	1,000.00	500.00
2025年	1,200.00	600.00
2026年	1,500.00	700.00
合計	3,700.00	1,800.00

▲ 以上計劃將根據公司實際經營情況及市場變化進行動態調整。我們將始終堅持以股東利益為重，不斷提升公司價值，為股東創造更多財富。

ix. Re-appointment of auditors of the Company

▲ 本公司審計師任期已屆滿，經股東大會決議，決定續聘原審計師繼續為本公司提供審計服務。原審計師在過去一年中表現專業、勤勉，為公司財務信息的真實、準確提供了有力保障。相關情況如下：

審計師姓名	任期 (年)
張三	2023-2024
李四	2024-2026

▲ 續聘決定符合公司利益，且能確保審計工作的連續性和穩定性。未來，我們將繼續加強與審計師的合作，共同提升公司財務管理水平。

LETTER FROM THE BOARD

3. ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES

2023年3月28日，本公司召开了2022年年度股东大会，审议通过了《2022年度利润分配方案》。根据该方案，公司拟以2022年12月31日的总股本为基数，向全体股东每10股派发现金股利人民币1.00元（含税）。

2023年4月10日，公司发布了《2022年度利润分配实施公告》，明确了本次利润分配的起止日期、实施对象及实施程序。自2023年4月10日起，公司将开始实施2022年度利润分配方案。

4. VOTING BY POLL

2023年3月28日，本公司召开了2022年年度股东大会，审议通过了《2022年度利润分配方案》。根据该方案，公司拟以2022年12月31日的总股本为基数，向全体股东每10股派发现金股利人民币1.00元（含税）。

5. RECOMMENDATION

2023年3月28日，本公司召开了2022年年度股东大会，审议通过了《2022年度利润分配方案》。根据该方案，公司拟以2022年12月31日的总股本为基数，向全体股东每10股派发现金股利人民币1.00元（含税）。

Shen hen Hepalink Pharmaceutical Group Co., Ltd.

Li Li
Chairman

NOTICE OF THE 2023 ANNUAL GENERAL MEETING



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
（A joint stock company incorporated in the People's Republic of China with limited liability）
（Stock code: 9989）

NOTICE OF THE 2023 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN

AGM

Company

ORDINARY RESOLUTIONS

NOTICE OF THE 2023 ANNUAL GENERAL MEETING

ORDINARY RESOLUTIONS

- 1. To approve the financial statements for the year ended 31 December 2023.
- 2. To approve the directors' report and financial statements for the year ended 31 December 2023.
- 3. To approve the dividend for the year ended 31 December 2023.

Shen hen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Notes:
1. The financial statements for the year ended 31 December 2023 are available on the company's website.

Notes:

- 1. The financial statements for the year ended 31 December 2023 are available on the company's website.
- 2. The directors' report and financial statements for the year ended 31 December 2023 are available on the company's website.
- 3. The dividend for the year ended 31 December 2023 is available on the company's website.
- 4. The financial statements for the year ended 31 December 2023 are available on the company's website.
- 5. The financial statements for the year ended 31 December 2023 are available on the company's website.
- 6. The financial statements for the year ended 31 December 2023 are available on the company's website.
- 7. The financial statements for the year ended 31 December 2023 are available on the company's website.
- 8. The financial statements for the year ended 31 December 2023 are available on the company's website.
- 9. The financial statements for the year ended 31 December 2023 are available on the company's website.
- 10. The financial statements for the year ended 31 December 2023 are available on the company's website.